Prof Arun Azad
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
503 Scholarly works
10 Projects
HIGHLIGHTS
2026
Journal article
Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide
DOI: 10.1200/JCO-24-028292026
Journal article
Thrombotic Microangiopathy in Patients Treated with 177Lu-PSMA Combination Therapies.
DOI: 10.2967/jnumed.126.2720852026
Journal article
ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients
DOI: 10.1016/j.eururo.2025.12.0212026
Journal article
Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
DOI: 10.1016/j.annonc.2026.01.0152023
Research grants (ARC, NHMRC, MRFF)
Optimising Radiopharmaceutical Therapy to Improve Clinical Outcomes in Advanced Prostate Cancer
2019
Research Grant
Up-Front Psma Alliance: Using Theranostics Early to Eradicate Prostate Cancer and Developing Novel Startegies for Psma-Negative Disease
2018
Research Grant
Vca Clinical Research Fellowship
RECENT SCHOLARLY WORKS
2026
Journal article
Re: Niraparib and Abiraterone Acetate plus Prednisone for HRR-deficient Metastatic Castration-sensitive Prostate Cancer: A Randomized Phase 3 Trial
DOI: 10.1016/j.eururo.2025.12.0082026
Journal article
Evaluation of PSA decline patterns in the Chinese subgroup of LIBERTAS, a phase 3 study of apalutamide plus continuous versus intermittent androgen deprivation therapy in metastatic castration-sensitive prostate cancer.
DOI: 10.1200/jco.2026.44.7_suppl.1542026
Journal article
Registry-based randomised phase II study of Enzalutamide versus Abiraterone: assessing cognitive function in eLderly patients with metastatic castration-resistant Prostate cancer (REAL-Pro).
DOI: 10.1016/j.esmorw.2025.1006772026
Journal article
P0350 Biochemical recurrence and safety in patients with high-risk localised prostate cancer treated with [177Lu] Lu-PSMA-617 prior to prostatectomy: Follow-up of the LuTectomy trial
DOI: 10.1016/s0302-2838(26)01246-72026
Journal article
IDeate-Prostate01: A phase 3, randomized, open-label study of ifinatamab deruxtecan versus docetaxel in participants with previously treated metastatic castration-resistant prostate cancer.
DOI: 10.1200/jco.2026.44.7_suppl.tps2942026
Journal article
Saruparib androgen receptor pathway inhibitor (ARPI) androgen deprivation therapy (ADT) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): The phase 1/2 PETRANHA trial.
DOI: 10.1200/jco.2026.44.7_suppl.177
RECENT PROJECTS
2026
Research grants (ARC, NHMRC, MRFF)
Understanding Biomarkers of Response and Resistance to 177-Lutetium-Psma (LuPSMA) in Metastatic Castrate-Resistant Prostate Cancer
2023
Research grants (other domestic)
Using Liquid Biopsies to Optimise Prostate Cancer Radionuclide Therapy